Breaking News, Collaborations & Alliances

PhoreMost, Boehringer Enter Drug Discovery Alliance

Will leverage PhoreMost’s SITESEEKER platform to identify novel targets for Boehringer’s discovery programs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PhoreMost Ltd., a UK-based biopharmaceutical company dedicated to ‘undruggable’ disease targets, has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim. Under the agreement, PhoreMost will receive an upfront payment and research funding as well as success-based milestones. Financial details were not disclosed. PhoreMost will leverage its next-generation phenotypic screening platform, SITESEEKER, towards disease relevant pathways nominated by Boehringer. Novel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters